C4X Discovery Holdings plc is a pharmaceutical research firm based in Manchester, United Kingdom, specializing in the discovery of new drugs. The company leverages advanced proprietary technologies for drug discovery, including Taxonomy3, an innovative computational platform employing unique mathematical algorithms to conduct intricate multi-variable analysis of genetic information. Additionally, Conformetrix provides a technology to precisely determine the three-dimensional structures of unbound drug molecules using experimental data, furnishing medicinal chemists with unparalleled understanding of their physical characteristics and how they behave. Its 4Sight tool further enables the visualization of four-dimensional molecules within a virtual reality environment. The company's development pipeline features several promising candidates: an Orexin-1 receptor antagonist aimed at addictive disorders; an NRF-2 activator targeting various inflammatory conditions; an IL-17A inhibitor for inflammation and autoimmune responses; α4β7 integrin inhibitors developed for inflammatory bowel disease; and MALT-1 inhibitors designed to combat hematological cancers. C4X Discovery has established significant collaborations with key industry players such as Sanofi, GEN-COVID, LifeArc, Indivior PLC, Phoremost, AstraZeneca UK Limited, and Evotec SE. Established in 2007, the company initially traded as Schosween 24 plc before adopting its current name, C4X Discovery Holdings plc, in October 2014.